Article ; Online: COVID-19 vaccine reactogenicity - A cohort event monitoring study in the Netherlands using patient reported outcomes.
2022 Volume 40, Issue 7, Page(s) 970–976
Abstract: ... after the first dose of COVID-19 vaccine in the Netherlands.: Design: A web-based prospective cohort ... design using patient reported outcomes (PROs).: Setting: Any person who has been vaccinated ... with the occurrence of reactogenicity after COVID-19 vaccination.: Results: Compared to the Comirnaty® vaccine ...
| Abstract | Objectives: To explore factors that are associated with reactogenicity in general and systemic after the first dose of COVID-19 vaccine in the Netherlands. Design: A web-based prospective cohort design using patient reported outcomes (PROs). Setting: Any person who has been vaccinated with any brand of COVID-19 vaccine in the Dutch COVID immunization programme. Participants: 22,184 participants. Of these, 13,959 (62.9%) experienced reactogenicity in general and 11,979 (54.0%) systemic reactogenicity within 7 days after vaccination. Main outcome measures: Factors that are associated with the occurrence of reactogenicity after COVID-19 vaccination. Results: Compared to the Comirnaty® vaccine, the highest odds ratio (OR) for developing reactogenicity was for the Vaxzevria® vaccine (OR 5.18) followed by Spikevax® (OR 2.16), and Janssen (OR 1.65). Participants with a history of COVID-19 disease had a 3.10 increased odds for reactogenicity. Women had a 2.08 increased odds compared to men. Older participants experienced less reactogenicity. Compared to the age group < 50, the ORs for the age groups 50-60, 61-79, and ≥80 were 0.36, 0.15, and 0.10 respectively. The use of an antipyretic drug, or a drug for nervous system disorders gave an increased odds of 1.34 and 1.16 respectively. A body mass index of 25.0-29.9 and over 30 was negatively associated with reactogenicity (OR 0.87 and OR 0.72 respectively). Comorbidities that were associated with reactogenicity were cardiac disorders (OR 1.26), respiratory disorders (OR 1.31), psychiatric disorders (1.37), reproductive disorders (OR 1.54), and eye disorders (OR 1.55). The factors associated with systemic reactogenicity were mostly comparable, but there were differences for comorbidities, drug use, and the strength of the regression coefficient. Conclusions: This extensive study with over 22,000 vaccine recipients in the Netherlands demonstrated that, taken into account all factors in the model, the Comirnaty® vaccine gave the least and the Vaxzevria® vaccine the most reactogenicity in general and systemic after the first dose. Also a person with a history of COVID-19 disease, female sex and younger age had an increased odds for experiencing reactogenicity after vaccination. |
|---|---|
| MeSH term(s) | COVID-19 ; COVID-19 Vaccines ; Female ; Humans ; Male ; Netherlands ; Patient Reported Outcome Measures ; Prospective Studies ; SARS-CoV-2 |
| Chemical Substances | COVID-19 Vaccines |
| Language | English |
| Publishing date | 2022-01-17 |
| Publishing country | Netherlands |
| Document type | Journal Article ; Research Support, Non-U.S. Gov't |
| ZDB-ID | 605674-x |
| ISSN | 1873-2518 ; 0264-410X |
| ISSN (online) | 1873-2518 |
| ISSN | 0264-410X |
| DOI | 10.1016/j.vaccine.2022.01.013 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 1930: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MO 458: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.